-
2
-
-
68849085858
-
Models for prevention and treatment of cancer: problems vs promises
-
Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009; 78: 1083-94.
-
(2009)
Biochem Pharmacol.
, vol.78
, pp. 1083-1094
-
-
Aggarwal, B.B.1
Danda, D.2
Gupta, S.3
Gehlot, P.4
-
3
-
-
84862814438
-
A Review on Various Targeted Anticancer Therapies
-
Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, et al. A Review on Various Targeted Anticancer Therapies. Targeted Oncol. 2012; 7: 69-85.
-
(2012)
Targeted Oncol.
, vol.7
, pp. 69-85
-
-
Li, J.1
Chen, F.2
Cona, M.M.3
Feng, Y.4
Himmelreich, U.5
Oyen, R.6
-
4
-
-
0026067043
-
Cancer metastasis
-
Fidler IJ. Cancer metastasis. Br Med Bull. 1991; 47: 157-77.
-
(1991)
Br Med Bull.
, vol.47
, pp. 157-177
-
-
Fidler, I.J.1
-
5
-
-
33644846740
-
CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape
-
Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol. 2006; 176: 3374-82.
-
(2006)
J Immunol.
, vol.176
, pp. 3374-3382
-
-
Liu, K.1
Caldwell, S.A.2
Greeneltch, K.M.3
Yang, D.4
Abrams, S.I.5
-
7
-
-
79960836519
-
MRI & MRS assessment of the role of the tumour microenvironment in response to therapy
-
Bell LK, Ainsworth NL, Lee SH, Griffiths JR. MRI & MRS assessment of the role of the tumour microenvironment in response to therapy. NMR Biomed. 2011; 24: 612-35.
-
(2011)
NMR Biomed.
, vol.24
, pp. 612-635
-
-
Bell, L.K.1
Ainsworth, N.L.2
Lee, S.H.3
Griffiths, J.R.4
-
9
-
-
0036381439
-
Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin
-
Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm. 2002; 17: 359-70.
-
(2002)
Cancer Biother Radiopharm.
, vol.17
, pp. 359-370
-
-
Khawli, L.A.1
Mizokami, M.M.2
Sharifi, J.3
Hu, P.4
Epstein, A.L.5
-
11
-
-
84860390456
-
A Dual-targeting Anticancer Approach: Soil and Seed Principle
-
Li J, Sun Z, Zhang J, Shao H, Miranda Cona M, et al. A Dual-targeting Anticancer Approach: Soil and Seed Principle. Radiology. 2011; 260:799-807.
-
(2011)
Radiology.
, vol.260
, pp. 799-807
-
-
Li, J.1
Sun, Z.2
Zhang, J.3
Shao, H.4
Miranda Cona, M.5
-
13
-
-
33644832204
-
Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin
-
Papadimitriou D, Kottou S, Oros L, Ilias I, Molfetas M, et al. Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin. Annals of Nuclear Medicine. 2006; 20: 63-67.
-
(2006)
Annals of Nuclear Medicine.
, vol.20
, pp. 63-67
-
-
Papadimitriou, D.1
Kottou, S.2
Oros, L.3
Ilias, I.4
Molfetas, M.5
-
14
-
-
0032053823
-
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy
-
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16.
-
(1998)
Cancer Res
, vol.58
, pp. 1408-1416
-
-
Brown, J.M.1
Giaccia, A.J.2
-
15
-
-
0036488496
-
Specialization of tumour vasculature
-
Ruoslahti E. Specialization of tumour vasculature. Nature Reviews Cancer. 2012; 2: 83-90.
-
(2012)
Nature Reviews Cancer.
, vol.2
, pp. 83-90
-
-
Ruoslahti, E.1
-
16
-
-
0026011103
-
Angiogenic attack as a therapeutic strategy for cancer
-
Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol. 1991; 20: 103-12.
-
(1991)
Radiother Oncol.
, vol.20
, pp. 103-112
-
-
Denekamp, J.1
Hill, S.2
-
17
-
-
33751583518
-
Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery
-
Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. Nat Clin Pract Oncol. 2006; 3: 682-92.
-
(2006)
Nat Clin Pract Oncol.
, vol.3
, pp. 682-692
-
-
Cooney, M.M.1
van Heeckeren, W.2
Bhakta, S.3
Ortiz, J.4
Remick, S.C.5
-
18
-
-
0032514402
-
Vascular targeting as a strategy for cancer therapy
-
Schnitzer JE. Vascular targeting as a strategy for cancer therapy. N Engl J Med. 1998; 339: 472-4.
-
(1998)
N Engl J Med.
, vol.339
, pp. 472-474
-
-
Schnitzer, J.E.1
-
19
-
-
0032535999
-
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
-
Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998; 279: 377-80.
-
(1998)
Science.
, vol.279
, pp. 377-380
-
-
Arap, W.1
Pasqualini, R.2
Ruoslahti, E.3
-
20
-
-
57749202046
-
Vascular targeted therapies in oncology
-
Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res. 2009; 335: 241-8.
-
(2009)
Cell Tissue Res.
, vol.335
, pp. 241-248
-
-
Siemann, D.W.1
Horsman, M.R.2
-
22
-
-
16844367677
-
Novel vascular targeting/ disrupting agents: combretastatin A4 phosphate and related compounds
-
Cooney MM, Ortiz J, Bukowski RM, Remick SC. Novel vascular targeting/ disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep. 2005; 7: 90-5.
-
(2005)
Curr Oncol Rep.
, vol.7
, pp. 90-95
-
-
Cooney, M.M.1
Ortiz, J.2
Bukowski, R.M.3
Remick, S.C.4
-
23
-
-
1642352048
-
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
-
Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer. 2004; 90: 906-10.
-
(2004)
Br J Cancer.
, vol.90
, pp. 906-910
-
-
Ching, L.M.1
Zwain, S.2
Baguley, B.C.3
-
24
-
-
33847247311
-
Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome
-
Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, et al. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia. 2007; 9:128-35.
-
(2007)
Neoplasia.
, vol.9
, pp. 128-135
-
-
Seshadri, M.1
Spernyak, J.A.2
Maiery, P.G.3
Cheney, R.T.4
Mazurchuk, R.5
-
25
-
-
33646342514
-
Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast- enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis
-
McPhail LD, McIntyre DJ, Ludwig C, Kestell P, Griffiths JR, et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast- enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia. 2006; 8: 199-206.
-
(2006)
Neoplasia.
, vol.8
, pp. 199-206
-
-
McPhail, L.D.1
McIntyre, D.J.2
Ludwig, C.3
Kestell, P.4
Griffiths, J.R.5
-
26
-
-
0033565644
-
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
-
Ching LM, Goldsmith D, Joseph WR, Körner H, Sedgwick JD, et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 1999; 59: 3304-7.
-
(1999)
Cancer Res.
, vol.59
, pp. 3304-3307
-
-
Ching, L.M.1
Goldsmith, D.2
Joseph, W.R.3
Körner, H.4
Sedgwick, J.D.5
-
27
-
-
84882991992
-
The Role of Modern Medical Imaging in Evaluation of Tumor Response to Vascular Targeting Therapy
-
ISBN 978-960-474-278-3
-
Wang H, Cona MM, Li J, Feng Y, Chen F, et al. The Role of Modern Medical Imaging in Evaluation of Tumor Response to Vascular Targeting Therapy. Recent Researches in Modern Medicine. 2009; ISBN: 978-960-474-278-3.
-
(2009)
Recent Researches in Modern Medicine.
-
-
Wang, H.1
Cona, M.M.2
Li, J.3
Feng, Y.4
Chen, F.5
-
28
-
-
29344471072
-
Understanding microtubule dynamics for improved cancer therapy
-
Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. 2005; 62: 3039-56.
-
(2005)
Cell Mol Life Sci.
, vol.62
, pp. 3039-3056
-
-
Honore, S.1
Pasquier, E.2
Braguer, D.3
-
29
-
-
78649833819
-
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
-
Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev. 2010; 37: 63-74.
-
(2010)
Cancer Treat Rev.
, vol.37
, pp. 63-74
-
-
Siemann, D.W.1
-
30
-
-
79953741443
-
A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment
-
Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb). 2011; 3: 375-87.
-
(2011)
Integr Biol (Camb).
, vol.3
, pp. 375-387
-
-
Mason, R.P.1
Zhao, D.2
Liu, L.3
Trawick, M.L.4
Pinney, K.G.5
-
31
-
-
55449122145
-
Tumour vascular disrupting agents: combating treatment resistance
-
Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, et al. Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol. 2008; 81: S12-20.
-
(2008)
Br J Radiol.
, vol.81
-
-
Tozer, G.M.1
Kanthou, C.2
Lewis, G.3
Prise, V.E.4
Vojnovic, B.5
-
32
-
-
33847048710
-
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications
-
Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol.2007; 170: 1-15.
-
(2007)
Am J Pathol.
, vol.170
, pp. 1-15
-
-
Dome, B.1
Hendrix, M.J.2
Paku, S.3
Tovari, J.4
Timar, J.5
-
33
-
-
64249135764
-
Novel agents on the horizon for cancer therapy
-
Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009; 59: 111-37.
-
(2009)
CA Cancer J Clin.
, vol.59
, pp. 111-137
-
-
Ma, W.W.1
Adjei, A.A.2
-
34
-
-
79953648492
-
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
-
Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011; 22: 2036-41.
-
(2011)
Ann Oncol.
, vol.22
, pp. 2036-2041
-
-
Zweifel, M.1
Jayson, G.C.2
Reed, N.S.3
Osborne, R.4
Hassan, B.5
-
35
-
-
0042386700
-
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results
-
Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003; 21: 2815-22.
-
(2003)
J Clin Oncol.
, vol.21
, pp. 2815-2822
-
-
Rustin, G.J.1
Galbraith, S.M.2
Anderson, H.3
Stratford, M.4
Folkes, L.K.5
-
37
-
-
0035417875
-
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability
-
Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001; 61: 6413-22.
-
(2001)
Cancer Res.
, vol.61
, pp. 6413-6422
-
-
Tozer, G.M.1
Prise, V.E.2
Wilson, J.3
Cemazar, M.4
Shan, S.5
-
38
-
-
66649086232
-
Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses
-
Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, et al. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res. 2009; 15: 3781-90.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 3781-3790
-
-
Tozer, G.M.1
Prise, V.E.2
Lewis, G.3
Xie, S.4
Wilson, I.5
-
39
-
-
34247173906
-
Characterizing the tumor response to treatment with combretastatin A4 phosphate
-
Salmon BA, Siemann DW. Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys. 2007; 68: 211-7.
-
(2007)
Int J Radiat Oncol Biol Phys.
, vol.68
, pp. 211-217
-
-
Salmon, B.A.1
Siemann, D.W.2
-
40
-
-
77951667223
-
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
-
Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer. 2010; 102: 1355-60.
-
(2010)
Br J Cancer.
, vol.102
, pp. 1355-1360
-
-
Rustin, G.J.1
Shreeves, G.2
Nathan, P.D.3
Gaya, A.4
Ganesan, T.S.5
-
41
-
-
67249095624
-
Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors
-
Mitrus I, Sochanik A, Cichon T, Szala S. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochim Pol. 2009; 56: 161-5.
-
(2009)
Acta Biochim Pol.
, vol.56
, pp. 161-165
-
-
Mitrus, I.1
Sochanik, A.2
Cichon, T.3
Szala, S.4
-
42
-
-
20044395276
-
Phase I trial of combretastatin a-4 phosphate with carboplatin
-
Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res. 2005; 11: 1527-33.
-
(2005)
Clin Cancer Res.
, vol.11
, pp. 1527-1533
-
-
Bilenker, J.H.1
Flaherty, K.T.2
Rosen, M.3
Davis, L.4
Gallagher, M.5
-
43
-
-
42449123761
-
Expansion and evolution of cell death programmes
-
Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol. 2008; 9: 378-90.
-
(2008)
Nat Rev Mol Cell Biol.
, vol.9
, pp. 378-390
-
-
Degterev, A.1
Yuan, J.2
-
44
-
-
0031719489
-
Actinobacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells
-
Korostoff J, Wang JF, Kieba I, Miller M, Shenker BJ, et al. Actinobacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells. Infect Immun. 1998; 66: 4474-83.
-
(1998)
Infect Immun.
, vol.66
, pp. 4474-4483
-
-
Korostoff, J.1
Wang, J.F.2
Kieba, I.3
Miller, M.4
Shenker, B.J.5
-
45
-
-
77955133412
-
Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA
-
Dasari M, Lee S, Sy J, Kim D, Brown M, et al. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Org Lett. 2010; 12: 3300-3.
-
(2010)
Org Lett.
, vol.12
, pp. 3300-3303
-
-
Dasari, M.1
Lee, S.2
Sy, J.3
Kim, D.4
Brown, M.5
-
47
-
-
22844434974
-
Necrosis avid contrast agents: functional similarity versus structural diversity
-
Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol. 2005; 40: 526-35.
-
(2005)
Invest Radiol.
, vol.40
, pp. 526-535
-
-
Ni, Y.1
Bormans, G.2
Chen, F.3
Verbruggen, A.4
Marchal, G.5
-
48
-
-
0029347647
-
Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings
-
Ni Y, Marchal G, Yu J, Lukito G, Petre C, et al. Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings. Acad Radiol.1995; 2: 687-99.
-
(1995)
Acad Radiol.
, vol.2
, pp. 687-699
-
-
Ni, Y.1
Marchal, G.2
Yu, J.3
Lukito, G.4
Petre, C.5
-
49
-
-
0026784206
-
Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer
-
Ni Y, Marchal G, van Damme B, van Hecke P, Michiels J, et al. Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer. Invest Radiol. 1992; 27: 689-97.
-
(1992)
Invest Radiol.
, vol.27
, pp. 689-697
-
-
Ni, Y.1
Marchal, G.2
van Damme, B.3
van Hecke, P.4
Michiels, J.5
-
50
-
-
0037655063
-
Non-invasive in vivo imaging of myocardial apoptosis and necrosis
-
Flotats A, Carrio I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging. 2003; 30: 615-30.
-
(2003)
Eur J Nucl Med Mol Imaging.
, vol.30
, pp. 615-630
-
-
Flotats, A.1
Carrio, I.2
-
51
-
-
0031451125
-
Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis
-
Ni Y, Petre C, Miao Y, Yu J, Cresens E, et al. Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol. 1997; 32: 770-779.
-
(1997)
Invest Radiol.
, vol.32
, pp. 770-779
-
-
Ni, Y.1
Petre, C.2
Miao, Y.3
Yu, J.4
Cresens, E.5
-
52
-
-
0035128069
-
MRI contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction
-
Ni Y, Adzamli K, Miao Y, Cresens E, Yu J, et al. MRI contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction. Invest Radiol. 2001; 36: 97-103.
-
(2001)
Invest Radiol.
, vol.36
, pp. 97-103
-
-
Ni, Y.1
Adzamli, K.2
Miao, Y.3
Cresens, E.4
Yu, J.5
-
53
-
-
45949097340
-
Metalloporphyrins and Functional Analogues as MRI Contrast Agents
-
Ni Y. Metalloporphyrins and Functional Analogues as MRI Contrast Agents. Current Medical Imaging Reviews. 2008; 4: 96-112.
-
(2008)
Current Medical Imaging Reviews.
, vol.4
, pp. 96-112
-
-
Ni, Y.1
-
54
-
-
66149142228
-
Vessel growth and function: depiction with contrast-enhanced MR imaging
-
Oostendorp M, Post MJ, Backes WH. Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology. 2009; 251: 317-35.
-
(2009)
Radiology.
, vol.251
, pp. 317-335
-
-
Oostendorp, M.1
Post, M.J.2
Backes, W.H.3
-
55
-
-
0026595006
-
Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging
-
Weissleder R, Lee A, Khaw B, Shen T, Brady T. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology.1992; 182: 381-5.
-
(1992)
Radiology.
, vol.182
, pp. 381-385
-
-
Weissleder, R.1
Lee, A.2
Khaw, B.3
Shen, T.4
Brady, T.5
-
56
-
-
0017811473
-
The prognostic implications of acute myocardial infarct scintigraphy with 99mTc-pyrophosphate
-
Holman BL, Chisholm RJ, Braunwald E. The prognostic implications of acute myocardial infarct scintigraphy with 99mTc-pyrophosphate. Circulation. 1978; 57: 320-6.
-
(1978)
Circulation.
, vol.57
, pp. 320-326
-
-
Holman, B.L.1
Chisholm, R.J.2
Braunwald, E.3
-
57
-
-
0016431601
-
Technetium-99m-pyrophosphate: studies in vivo and in vitro
-
Kaye M, Silverton S, Rosenthall L. Technetium-99m-pyrophosphate: studies in vivo and in vitro. J Nucl Med.1975; 16: 40-5.
-
(1975)
J Nucl Med.
, vol.16
, pp. 40-45
-
-
Kaye, M.1
Silverton, S.2
Rosenthall, L.3
-
58
-
-
33646396784
-
First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent
-
Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging. 2006; 33: 595-601.
-
(2006)
Eur J Nucl Med Mol Imaging.
, vol.33
, pp. 595-601
-
-
Ni, Y.1
Huyghe, D.2
Verbeke, K.3
de Witte, P.A.4
Nuyts, J.5
-
59
-
-
66349091301
-
Molecular imaging of cell death
-
De Saint-Hubert M, Prinsen K, Mortelmans L, Verbruggen A, Mottaghy F. Molecular imaging of cell death. Methods. 2009; 48: 178-87.
-
(2009)
Methods.
, vol.48
, pp. 178-187
-
-
De Saint-Hubert, M.1
Prinsen, K.2
Mortelmans, L.3
Verbruggen, A.4
Mottaghy, F.5
-
60
-
-
77649229910
-
Hypericins as Potential Leads for New Therapeutics
-
Karioti A, Bilia AR. Hypericins as Potential Leads for New Therapeutics. Int J Mol Sci. 2010; 11: 562-594.
-
(2010)
Int J Mol Sci.
, vol.11
, pp. 562-594
-
-
Karioti, A.1
Bilia, A.R.2
-
61
-
-
0035315837
-
Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy
-
Chen B, Zupko I, de Witte PA. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int J Oncol. 2001; 18: 737-42.
-
(2001)
Int J Oncol.
, vol.18
, pp. 737-742
-
-
Chen, B.1
Zupko, I.2
de Witte, P.A.3
-
62
-
-
0036878574
-
Antivascular tumor eradication by hypericin-mediated photodynamic therapy
-
Chen B, Roskams T, de Witte PA. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol. 2002; 76: 509-13.
-
(2002)
Photochem Photobiol.
, vol.76
, pp. 509-513
-
-
Chen, B.1
Roskams, T.2
de Witte, P.A.3
-
64
-
-
0030922812
-
Binding, uptake, and transport of hypericin by Caco-2 cell monolayers
-
Sattler S, Schaefer U, Schneider W. Hoelzl J, Lehr CM. Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. J Pharm Sci.1997; 86: 1120-6.
-
(1997)
J Pharm Sci.
, vol.86
, pp. 1120-1126
-
-
Sattler, S.1
Schaefer, U.2
Schneider, W.3
Hoelzl, J.4
Lehr, C.M.5
-
65
-
-
0026873378
-
Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells
-
Thomas C, Pardini RS. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem Photobiol. 1992; 55: 831-7.
-
(1992)
Photochem Photobiol.
, vol.55
, pp. 831-837
-
-
Thomas, C.1
Pardini, R.S.2
-
66
-
-
0030923774
-
Differential cytotoxic effects induced after photosensitization by hypericin
-
Vandenbogaerde AL, Cuveele JF, Proot P, Himpens BE, Merlevede WJ, et al. Differential cytotoxic effects induced after photosensitization by hypericin. J Photochem Photobiol B. 1997; 38: 136-42.
-
(1997)
J Photochem Photobiol B.
, vol.38
, pp. 136-142
-
-
Vandenbogaerde, A.L.1
Cuveele, J.F.2
Proot, P.3
Himpens, B.E.4
Merlevede, W.J.5
-
68
-
-
84860393902
-
-
European Patent, Belgium, Patent Application Ref No. LRD-GB-1-455
-
Ni Y, Bormans G, Marchal G, Verbruggen A. Necrosis avid tracer agent. European Patent, Belgium. 2003. Patent Application Ref No. LRD-GB-1-455.
-
(2003)
Necrosis avid tracer agent
-
-
Ni, Y.1
Bormans, G.2
Marchal, G.3
Verbruggen, A.4
-
69
-
-
34547538159
-
Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor
-
Fonge H, Van de Putte M, Huyghe D, Bormans G, Ni Y, et al. Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor. Contrast Media Mol Imaging.2007; 2: 113-9.
-
(2007)
Contrast Media Mol Imaging.
, vol.2
, pp. 113-119
-
-
Fonge, H.1
Van de Putte, M.2
Huyghe, D.3
Bormans, G.4
Ni, Y.5
-
70
-
-
38649131018
-
Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT
-
Fonge H, Vunckx K, Wang H, Feng Y, Mortelmans L, et al. Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur Heart J. 2008; 29: 260-9.
-
(2008)
Eur Heart J.
, vol.29
, pp. 260-269
-
-
Fonge, H.1
Vunckx, K.2
Wang, H.3
Feng, Y.4
Mortelmans, L.5
-
71
-
-
43849086304
-
Exploration of the mechanism underlying the tumor necrosis avidity of hypericin
-
Van de Putte M, Ni Y, De Witte PA. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep. 2008; 19: 921-6.
-
(2008)
Oncol Rep.
, vol.19
, pp. 921-926
-
-
Van de Putte, M.1
Ni, Y.2
De Witte, P.A.3
-
72
-
-
43849086838
-
Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model
-
Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep. 2008; 19: 927-32.
-
(2008)
Oncol Rep.
, vol.19
, pp. 927-932
-
-
Van de Putte, M.1
Wang, H.2
Chen, F.3
De Witte, P.A.4
Ni, Y.5
-
73
-
-
36749065586
-
Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model
-
Van de Putte M, Wang H, Chen F, de Witte PA, Ni Y. Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol. 2008; 15: 107-13.
-
(2008)
Acad Radiol.
, vol.15
, pp. 107-113
-
-
Van de Putte, M.1
Wang, H.2
Chen, F.3
de Witte, P.A.4
Ni, Y.5
-
75
-
-
0023784524
-
A novel method for the detection of necrotic lesions in human cancers
-
Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res.1988; 48: 5842-8.
-
(1988)
Cancer Res.
, vol.48
, pp. 5842-5848
-
-
Epstein, A.L.1
Chen, F.M.2
Taylor, C.R.3
-
76
-
-
84867865246
-
Continuing pursuit for ideal systemic anticancer radiotherapeutics
-
Cona MM, Wang H, Li J, Feng Y, Chen F, et al. Continuing pursuit for ideal systemic anticancer radiotherapeutics. Invest New Drugs. 2012; 30:2050-65.
-
(2012)
Invest New Drugs.
, vol.30
, pp. 2050-2065
-
-
Cona, M.M.1
Wang, H.2
Li, J.3
Feng, Y.4
Chen, F.5
-
77
-
-
0026683490
-
Radioimmunotherapy of cancer: arming the missiles
-
Goldenberg DM, Griffiths GL. Radioimmunotherapy of cancer: arming the missiles. J Nucl Med. 1992; 33: 1110-2.
-
(1992)
J Nucl Med.
, vol.33
, pp. 1110-1112
-
-
Goldenberg, D.M.1
Griffiths, G.L.2
-
78
-
-
15244351004
-
Overview of monoclonal antibodies in cancer therapy: present and promise
-
Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005; 54: 11-29.
-
(2005)
Crit Rev Oncol Hematol.
, vol.54
, pp. 11-29
-
-
Stern, M.1
Herrmann, R.2
-
79
-
-
84862781827
-
Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential
-
Van de Putte M, Marysael T, Fonge H, Roskams T, Cona MM, et al. Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer. 2011; 131: 129-137
-
(2011)
Int J Cancer.
, vol.131
, pp. 129-137
-
-
Van de Putte, M.1
Marysael, T.2
Fonge, H.3
Roskams, T.4
Cona, M.M.5
-
80
-
-
17944383454
-
Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging
-
Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, et al. Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol. 2001; 11: 876-83.
-
(2001)
Eur Radiol.
, vol.11
, pp. 876-883
-
-
Ni, Y.1
Pislaru, C.2
Bosmans, H.3
Pislaru, S.4
Miao, Y.5
-
81
-
-
33750823665
-
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
-
Ginj M, Zhang H, Waser B, Cescato R, Wild D, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006; 103: 16436-41.
-
(2006)
Proc Natl Acad Sci U S A.
, vol.103
, pp. 16436-16441
-
-
Ginj, M.1
Zhang, H.2
Waser, B.3
Cescato, R.4
Wild, D.5
-
82
-
-
84883006320
-
Systemic Sequential Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin: Synergistic Targeted Anticancer Effect with Prolonged Survival in a Murine Model of Subcutaneous Tumor Xenografts
-
(In press)
-
Li J, Cona MM, Chen F, Zhou L, Nuyts J, et al. Systemic Sequential Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin: Synergistic Targeted Anticancer Effect with Prolonged Survival in a Murine Model of Subcutaneous Tumor Xenografts. Theranostics. (In press).
-
Theranostics
-
-
Li, J.1
Cona, M.M.2
Chen, F.3
Zhou, L.4
Nuyts, J.5
-
83
-
-
78650317418
-
Nanoparticle-assisted combination therapies for effective cancer treatment
-
Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic Delivery. 2010; 1: 323-334.
-
(2010)
Therapeutic Delivery.
, vol.1
, pp. 323-334
-
-
Hu, C.M.1
Aryal, S.2
Zhang, L.3
-
84
-
-
33645051467
-
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC
-
Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist. 2006; 11: 274-84.
-
(2006)
Oncologist.
, vol.11
, pp. 274-284
-
-
Maione, P.1
Gridelli, C.2
Troiani, T.3
Ciardiello, F.4
-
85
-
-
80051769183
-
Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer
-
Wang H, Marchal G, Ni Y. Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol. 2011; 3: 1-16.
-
(2011)
World J Radiol.
, vol.3
, pp. 1-16
-
-
Wang, H.1
Marchal, G.2
Ni, Y.3
-
86
-
-
77956301345
-
Combretastatin A4 phosphate: a novel vascular disrupting agent
-
Nagaiah G, Remick SC. Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol. 2010; 6: 1219-28.
-
(2010)
Future Oncol.
, vol.6
, pp. 1219-1228
-
-
Nagaiah, G.1
Remick, S.C.2
-
87
-
-
49049086508
-
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503)
-
Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008; 28: 2027-31.
-
(2008)
Anticancer Res.
, vol.28
, pp. 2027-2031
-
-
Siemann, D.W.1
Shi, W.2
-
88
-
-
84855176809
-
Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck
-
Ng QS, Mandeville H, Goh V, Alonzi R, Milner J, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol. 2005; 23: 231-7.
-
(2005)
Ann Oncol.
, vol.23
, pp. 231-237
-
-
Ng, Q.S.1
Mandeville, H.2
Goh, V.3
Alonzi, R.4
Milner, J.5
-
89
-
-
80054760369
-
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors
-
Marysael T, Ni Y, Lerut E, de Witte P. Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. J Cancer Res Clin Oncol. 2011;137:1619-27.
-
(2011)
J Cancer Res Clin Oncol.
, vol.137
, pp. 1619-27
-
-
Marysael, T.1
Ni, Y.2
Lerut, E.3
de Witte, P.4
-
90
-
-
84870478186
-
Exploring Diagnostic and Therapeutic Potentials of Radioiodinated Hypericin in Animal Models of Pathologies
-
Li J, Cona MM, Chen F, Zhou L, Nuyts J, et al. Exploring Diagnostic and Therapeutic Potentials of Radioiodinated Hypericin in Animal Models of Pathologies. Theranostics. 2012; 2: 1010-1019.
-
(2012)
Theranostics.
, vol.2
, pp. 1010-101019
-
-
Li, J.1
Cona, M.M.2
Chen, F.3
Zhou, L.4
Nuyts, J.5
-
91
-
-
11844254414
-
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
-
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
-
(2005)
Science.
, vol.307
, pp. 58-62
-
-
Jain, R.K.1
-
92
-
-
53649083420
-
Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU
-
Verbruggen A, Coenen HH, Deverre JR, Guilloteau D, Langstrom B, Salvadori PA, Halldin C. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging. 2008; 35:2144-215.
-
(2008)
Eur J Nucl Med Mol Imaging.
, vol.35
, pp. 2144-215
-
-
Verbruggen, A.1
Coenen, H.H.2
Deverre, J.R.3
Guilloteau, D.4
Langstrom, B.5
Salvadori, P.A.6
Halldin, C.7
-
93
-
-
0036760384
-
Chemo-radionuclide therapy for thyroid cancer: Initial experimental study with cultured cells
-
Misaki T, Iwata M, Iida Y, Kasagi K, Konishi J. Chemo-radionuclide therapy for thyroid cancer: Initial experimental study with cultured cells. Annals of Nuclear Medicine. 2002; 16: 403-408
-
(2002)
Annals of Nuclear Medicine.
, vol.16
, pp. 403-4408
-
-
Misaki, T.1
Iwata, M.2
Iida, Y.3
Kasagi, K.4
Konishi, J.5
-
94
-
-
84879926744
-
A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [Iodogen] dissolved in dimethyl sulfoxide [DMSO]
-
epub
-
Cona MM, Li J, Chen F, Feng Y, Alpizar Y, et al. A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [Iodogen] dissolved in dimethyl sulfoxide [DMSO]. XENOBIOTICA 2013; epub.
-
(2013)
XENOBIOTICA
-
-
Cona, M.M.1
Li, J.2
Chen, F.3
Feng, Y.4
Alpizar, Y.5
-
95
-
-
84870510435
-
A Single-dose toxicity study in mice on non-radioactive iodinated hypericin for a targeted anticancer therapy
-
Li J. Cona MM, Feng Y, Chen F, Fu X, et al. A Single-dose toxicity study in mice on non-radioactive iodinated hypericin for a targeted anticancer therapy. Acta Pharmacologica Sinica. 2012; 33: 1549-1556.
-
(2012)
Acta Pharmacologica Sinica.
, vol.33
, pp. 1549-1556
-
-
Li, J.1
Cona, M.M.2
Feng, Y.3
Chen, F.4
Fu, X.5
-
96
-
-
34250377800
-
Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent
-
Fonge H, Jin L, Wang H, Ni Y, Bormans G, et al. Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent. Bioorg Med Chem Lett. 2007; 17: 4001-5.
-
(2007)
Bioorg Med Chem Lett.
, vol.17
, pp. 4001-4005
-
-
Fonge, H.1
Jin, L.2
Wang, H.3
Ni, Y.4
Bormans, G.5
-
97
-
-
1942534033
-
Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin
-
Bormans G, Huyghe D, Christiaen A, Verbeke K, de Groot T, et al. Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin. J Label Compd Radiopharm. 2004; 47: 191-198.
-
(2004)
J Label Compd Radiopharm.
, vol.47
, pp. 191-198
-
-
Bormans, G.1
Huyghe, D.2
Christiaen, A.3
Verbeke, K.4
de Groot, T.5
-
98
-
-
84873902064
-
Transbilayer phospholipids molecular imaging
-
Belhocine TZ, Prato FS. Transbilayer phospholipids molecular imaging. EJNMMI Res. 2011; 1: 17.
-
(2011)
EJNMMI Res.
, vol.1
, pp. 17
-
-
Belhocine, T.Z.1
Prato, F.S.2
-
99
-
-
0031905742
-
Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay
-
Watanabe N, Yokoyama K, Kinuya S, Shuke N, Shimizu M, et al. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. J Nucl Med.1998; 39: 436-40.
-
(1998)
J Nucl Med.
, vol.39
, pp. 436-440
-
-
Watanabe, N.1
Yokoyama, K.2
Kinuya, S.3
Shuke, N.4
Shimizu, M.5
-
101
-
-
0026482808
-
Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design
-
Narra VR, Howell RW, Harapanhalli RS, Sastry KS, Rao DV. Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design. J Nucl Med. 1992; 33: 2196-201.
-
(1992)
J Nucl Med.
, vol.33
, pp. 2196-2201
-
-
Narra, V.R.1
Howell, R.W.2
Harapanhalli, R.S.3
Sastry, K.S.4
Rao, D.V.5
-
102
-
-
0037096814
-
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer
-
Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002; 62: 3408-3416.
-
(2002)
Cancer Res.
, vol.62
, pp. 3408-3416
-
-
Dowlati, A.1
Robertson, K.2
Cooney, M.3
-
103
-
-
1642494772
-
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer
-
Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004; 10: 96-100.
-
(2004)
Clin Cancer Res.
, vol.10
, pp. 96-100
-
-
Cooney, M.M.1
Radivoyevitch, T.2
Dowlati, A.3
-
104
-
-
84874715009
-
Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography and Histopathology
-
DOI: 10.1593/tlo.12367
-
Li J, Chen F, Feng Y, Miranda Cona M, Yu J, et al. Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography and Histopathology. Translational Oncology. DOI: 10.1593/tlo.12367.
-
Translational Oncology
-
-
Li, J.1
Chen, F.2
Feng, Y.3
Miranda Cona, M.4
Yu, J.5
-
105
-
-
84864015478
-
Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI
-
Chen F, Feng Y, Zheng K, De Keyzer F, Li J, et al. Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI. PLoS ONE. 2012; 7: e41140.
-
(2012)
PLoS ONE.
, vol.7
-
-
Chen, F.1
Feng, Y.2
Zheng, K.3
De Keyzer, F.4
Li, J.5
|